

WEDNESDAY, 12 JUNE 2019**18.15 - 19.45****Hall 8****AbbVie****Achieving remission in RA: Elevating expectations****Chair(s):**

Peter Taylor (UK)

Peter Taylor (UK) 18.15

Welcome and introduction

Maya Buch (UK) 18.20

What defines remission?

Peter Taylor (UK) 18.35

Why drive for remission?

Claire Bombardier (CA) 18.55

Achieving remission in the real world

Peter Nash (AU) 19.15

Can new therapies elevate our expectations

All 19.35

Panel discussion and Q&A

18.15 - 19.45**Hall 7A****Pfizer****Exploring advanced therapeutic options in rheumatoid arthritis (RA) and psoriatic arthritis (PsA): A case-driven approach****Chair(s):**

Juan Gómez-Reino (ES)

Juan Gómez-Reino (ES) 18.15

Welcome and introductions

Janet Pope (CA) 18.20

Patients with inadequate response to csDMARDs in RA

Janet Pope (CA) 18.40

Patients who are candidates for monotherapy in RA

Douglas Veale (IR) 19.00

Patients presenting with joint symptoms and fatigue in PsA

James Galloway (UK) 19.20

Patients presenting with associated comorbidities in RA/PsA

Juan Gómez-Reino (ES) 19.40

Summary and close

18.15 - 19.45**Hall 7B****Sanofi Genzyme Regeneron****Metacognition in RA: Thinking about our thinking in RA management****Chair(s):**

Leonard Calabrese (US)

Leonard Calabrese (US) 18.15

Introduction: Is it possible to achieve better disease control in RA?

John Weinman (UK) 18.25

The role of patient beliefs in RA adherence and therapy optimisation

Daniel Aletaha (AT) 18.40

The ideal vs the norm: What does minimally important difference mean and why is this important in management of RA today?

Andrea Rubbert-Roth (CH) 18.55

Changes in daily RA practice: Dealing with loss vs gain in switching vs cycling

Leonard Calabrese (US) 19.10

Holistic care of patients with RA

All 19.20

Q&A

Leonard Calabrese (US) 19.40

Close

18.15 - 19.45**N101/N102****Novartis****Targeting clinical remission in Still's disease with interleukin-1 β inhibition****Chair(s):**

Sinisa Savic (UK)

Sinisa Savic (UK) 18.15

Welcome and introductions

Sinisa Savic (UK) 18.20

Still's disease – a devastating condition for young and adult patients

Eugen Feist (DE) 18.40IL-1 β inhibition in adult-onset Still's disease: From successful case experiences to clinical trials**Pierre Quartier (FR) 19.00**Flexibility in the management of systemic juvenile idiopathic arthritis with IL-1 β inhibition**All 19.20**

Panel discussion: Current and future perspectives on targeting remission

18.15 - 19.45

N117/N118

IBSA**Management of pain in osteoarthritis: From clinical guidelines to real life****Chair(s):**

Jean-Yves Reginster (BE)

Jean-Yves Reginster (BE)

Welcome and introduction

Marc Hochberg (US)

Current recommendations for the management of osteoarthritis

Alberto Migliore (IT)

OA treatment: One fits for all?

Alberto Migliore (IT)

Towards the appropriate choice of hyaluronic acid product for «my patient»

Jean-Yves Reginster (BE)

Efficacy and safety of a single intra-articular injection of high and low molecular weight hyaluronic acid in the symptomatic management of knee osteoarthritis

All

Discussion and conclusion

18.15 - 19.45

N111/N112

Fresenius Kabi**Beyond the joint: An integrated approach to rheumatoid arthritis****Chair(s):**

Josef S. Smolen (AT)

Josef S. Smolen (AT)

18.15

Welcome and introduction

Bruno Fautrel (FR)

18.25

Expanding access to biologics with biosimilars

Anne Tournadre (FR)**Chris Edwards (UK)**

18.45

Rheumatoid Arthritis (RA) – the impact of comorbidities: A focus on sarcopenia and mental health disorders

Chris Edwards (UK)

19.20

Management of RA patients beyond the disease

Josef S. Smolen (AT)

19.35

Conclusion and structured discussion

THURSDAY, 13 JUNE 2019

08.15 - 09.45

Hall 8

AbbVie**Therapeutic choice in RA: How should we be guided by patients?****Chair(s):**

Andrew Östör (AU)

Andrew Östör (AU)

08.15

Welcome and introduction

Jose Maria Alvaro-Gracia (ES)

08.25

The impact of RA on quality of life: The patient perspective

Lars Klareskog (SE)

08.40

Assessing patient outcomes in routine clinical practice: Can we do better?

David Walsh (UK)

08.55

Pain mechanisms and management in RA

Andrew Östör (AU)

09.10

Patient-centric therapeutic choice

All

09.30

Panel discussion and Q&A

08.15 - 09.45

Hall 7A

Novartis**Axial spondyloarthritis: Optimizing clinical management and future directions****Chair(s):**

Robert Landewé (NL)

Robert Landewé (NL)

08.15

Welcome and introduction

Robert Landewé (NL)

08.20

Radiographic and non-radiographic axSpA: Historical perspectives and current priorities

Georg Schett (DE)

08.35

Optimizing the axSpA patient journey: Clinical spectrum and pathophysiology

Lianne Gensler (US)

08.55

Clinical cases in axSpA management: Early diagnosis and assessment

Denis Poddubnyy (DE)

09.10

Therapies in the management of axSpA

All

09.30

Panel discussion and conclusions

08.15 - 09.45 Hall 7B

Roche

Putting new evidence into clinical practice in GCA and RA – together we dare

Chair(s):

John Stone (US)

John Stone (US)

New insights into the treatment of GCA

Frank Buttgerit (DE)

Strengthening the treatment paradigm in RA

All

Controversial topics debate and Q&A

08.15 - 09.45 N103/N104

Lilly

Elevating treatment goals in psoriatic arthritis

Chair(s):

Victoria Navarro-Compán (ES)

Lars Erik Kristensen (DK)

Victoria Navarro-Compán (ES)

Lars Erik Kristensen (DK) 08.15

Welcome and introduction

Lars Erik Kristensen (DK) 08.20

Can we elevate treatment goals for patients with psoriatic arthritis?

Dennis McGonagle (UK) 08.40

The leading role of IL-17's in the treatment of psoriatic arthritis

Peter Nash (AU) 09.00

Ixekizumab in the holistic management of psoriatic arthritis: SPIRIT head to head trial

All 09.20

Panel discussion: What does the data mean for patients?

08.15 - 09.45 N101/N102

medac

MTX remains gold standard in the era of biologics and new therapies

Chair(s):

Carter Thorne (CA)

Carter Thorne (CA) 08.15

Welcome and introduction

Carter Thorne (CA) 08.20

Benefits of subcutaneous vs oral methotrexate in RA treatment

Gerolamo Bianchi (IT) 08.45

Optimising MTX therapy to improve treatment outcomes

Pavia Dolezalova (CZ) 09.10

Improving treatment outcomes in patients with juvenile idiopathic arthritis

Carter Thorne (CA) 09.35

Summary and discussion

08.15 - 09.45 N105/N106

UCB

Considering the patient perspective: Challenges facing women with axSpA and PsA

Chair(s):

Irene van der Horst-Bruinsma (NL)

Irene van der Horst-Bruinsma (NL) 08.15

Welcome and introduction

Helena Marzo-Ortega (UK)

Kay Anderson (UK) 08.30

Expert discussion: axSpA

Laura Coates (UK)

Kay Anderson (UK) 09.00

Expert discussion: PsA

All 09.30

Summary and question and answer discussion

08.15 - 09.45 N117/N118

Biogen and Samsung Bioepis

Optimizing patient management in RA – Can we live up to patient expectations?

Chair(s):

Peter Taylor (UK)

Peter Taylor (UK) 08.15

Opening and introduction

Peter Taylor (UK)

Marco Matucci Cerinic (IT)

Ulf Mueller-Ladner (DE)

Ruth Slack (UK)

Thierry Thomas (FR) 08.30

1) Selecting the right treatment for the right patient at the right time: What drives our decision?

2) Patient expectations in RA

3) Addressing patient expectations: Through the eyes of a multidisciplinary team

Peter Taylor (UK) 09.40

Closing remarks

08.15 - 09.45**N111/N112****PeerVoice
supported by Sanofi Genzyme****IL-6 receptor inhibition in RA: New perspectives
in optimal patient care****Chair(s):**

Ernest Choy (UK)

Ernest Choy (UK)**08.15**

Welcome and introduction

Ernest Choy (UK)**08.20**IL-6 biology and implications for clinical
targeting in RA**Roberto Caporali (IT)****08.45**Differentiating IL-6R inhibitors from other
drug classes**Jacques-Eric Gottenberg (FR)****09.10**

Optimising IL-6R inhibition in clinical practice

Ernest Choy (UK)**09.35**

Conclusion

17.30 - 19.00**Hall 7A****AbbVie****Demystifying the systemic truths of SpA****Chair(s):**

Dirk Elewaut (BE)

Dirk Elewaut (BE)**17.30**

Welcome and introduction

Demystifying the journey from pathogenesis
to therapy**Dafna Gladman (CA)****17.55**Unmet needs in SpA: Not just the usual
suspects**Laura Coates (UK)****18.20**Integrated, personalised, connected...SpA
2025**All****18.40**

Panel discussion and Q&A

17.30 - 19.00**Hall 7B****Medscape
supported by Pfizer and Lilly****Managing chronic pain in osteoarthritis:
Pushing back the frontier with targeted therapies****Chair(s):**

Richard Langford (UK)

Faculty:

Francis Berenbaum (FR)

Bart Morlion (BE)

Cécile Overman (NL)

Part 1: Treatment strategies for osteoarthritis-
associated pain: A case journeyPart 2: OA- associated chronic pain: What is the
therapeutic "frontier"?

Closing

17.30 - 19.00**N101/N102****Janssen****Fine-tuning the treatment of PsA: Focus on the
IL-23 pathway****Chair(s):**

Georg Schett (DE)

Peter Taylor (UK)

Georg Schett (DE)**Peter Taylor (UK)****17.30**

Welcome and introduction

Stefan Siebert (UK)**17.35**The promise and delivery of targeting the
IL-12/23 pathway**Georg Schett (DE)****17.50**

Focus on the IL-23 pathway

Peter Taylor (UK)**18.05**Targeting IL-23: What could this mean in
practice?**Lluís Puig (ES)****18.20**

Experience of targeting IL-23 in dermatology

All**18.35**

Panel discussion and Q&A

Georg Schett (DE)**Peter Taylor (UK)****18.55**

Conclusions and close of meeting

17.30 - 19.00 N105/N106

Bristol-Myers Squibb

Beyond the joint: The role of pathogenic autoantibodies in system manifestations of RA

Chair(s):

Bernard Combe (FR)

Bernard Combe (FR) 17.30

Welcome and introduction

Jens Thiel (DE) 17.35

The course of systemic RA disease: The role of pathogenic autoantibodies

José María Álvaro-Gracia (ES) 17.55

Unseen epidemic: Causes and consequences of RA-associated ILD

Laura Geraldino-Pardilla (US) 18.20

Double trouble: Autoimmunity and inflammation link to cardiovascular risk in RA

All 18.45

Symposium summary, panel discussion and close

17.30 - 19.00 N117/N118

GSK

Treatment timing considerations in biologic management of SLE: The long and short of it

Chair(s):

Alejandro Olivé-Marqués (ES)

Alejandro Olivé-Marqués (ES) 17.30

Welcome and introduction

Alejandro Olivé-Marqués (ES) 17.35

Long- and short-term treatment goals in SLE

José A. Gómez-Puerta (ES) 17.45

Balancing the benefits and risks of treatment in SLE

Luca Iaccarino (IT) 18.05

When to start biologic therapy in SLE?

Andreas Schwarting (DE) 18.25

Experience with initiating biologic therapy earlier in the disease course

All 18.40

Faculty discussions

Alejandro Olivé-Marqués (ES) 18.55

Summing up and concluding remarks

17.30 - 19.00 N111/N112

Celltrion Healthcare

Redesigning the future of RA treatment with Infliximab SC

Chair(s):

Rieke Alten (DE)

Rieke Alten (DE) 17.30

Welcome and introduction

DaeHyun Yoo (KR) 17.40

Real-world safety, efficacy and drug survival of CT-P13

Rene Westhovens (BE) 18.10

Clinical findings on CT-P13 SC

All 18.40

Panel discussion

FRIDAY, 14 JUNE 2019

08.15 - 09.45 Hall 7A

Novartis

IL-17A inhibition in psoriatic arthritis: Comprehensive treatment across disease manifestations

Chair(s):

Paul Emery (UK)

Paul Emery (UK) 08.15

Welcome and introduction

Ellen Gravallesse (US) 08.20

Effects of the IL-17 pathway on inflammation, enthesitis, and bone in PsA

Xenofon Baraliakos (DE) 08.35

Back pain in PsA and axSpA: A critical comparison

Mikkel Østergaard (DK) 08.55

Real world evidence: The importance of comprehensive disease control

Peter Nash (AU) 09.10

IL-17A inhibition and data visualization: Comprehensive treatment for PsA

All 09.30

Panel discussion and conclusions

08.15 - 09.45**Hall 7B****Boehringer Ingelheim****Treatment of interstitial lung disease in systemic sclerosis and other autoimmune rheumatic diseases – A step forward****Chair(s):**

Oliver Distler (CH)

Oliver Distler (CH)**08.15**

Introduction

Anna-Maria Hoffmann-Vold (NO)**08.20**

How should we screen for and monitor SSc-ILD?

Clive Kelly (UK)**08.40**

Can we apply learnings from SSc-ILD to the screening and monitoring of ILDs in other autoimmune rheumatic diseases?

Oliver Distler (CH)**09.00**

Are we a step closer to a new approach to the treatment of SSc-ILD and other ILDs associated with autoimmune rheumatic diseases?

All**09.20**

Questions and answers

08.15 - 09.45**N103/N104****Lilly****The standard of care in rheumatoid arthritis: The BAR Is RAised****Chair(s):**

José María Álvaro-Gracia (ES)

Ronald van Vollenhoven (NL)

José María Álvaro-Gracia (ES)**Ronald van Vollenhoven (NL)****08.15**

Welcome and introduction

Ernest Choy (UK)**08.20**

Is there any new evidence on JAK inhibition and its clinical implications?

Peter Taylor (UK)**08.40**

Treating to target and beyond

Eugen Feist (DE)**09.00**

The test drive is over: What have we learnt using Baricitinib in clinical practice?

José María Álvaro-Gracia (ES)**Ronald van Vollenhoven (NL)****09.20**

Panel discussion and Q&A

08.15 - 09.45**N101/N102****AbbVie****Transition to adulthood in clinical practice: How can we improve the experience of patients with JIA?****Chair(s):**

Alberto Martini (IT)

Alberto Martini (IT)**08.15**

Welcome, introduction and objectives

Alberto Martini (IT)**08.20**

Understanding the journey of a patient with JIA: The changing needs throughout adolescence into adulthood

Helen Foster (UK)**08.40**

Assessing and transforming transition strategies: What do the guidelines advise?

Cristina Estrach (UK)**09.00**

Setting up a successful transition service: What do I need to know?

Helen Foster (UK)**Cristina Estrach (UK)****09.15**

Practical implementation: Case reports on the successful transition of patients with JIA

All**09.35**

Panel discussion and Q&A

08.15 - 09.45**N105/N106****Celgene****Moderate PsA and perspectives from PDE4 inhibition****Chair(s):**

Rubén Queiro (ES)

Rubén Queiro (ES)**08.15**

Opening statements

Stefan Siebert (UK)**08.20**

Challenges in PsA clinical practice: Tailoring treatment to patients' profile

Dafna Gladman (CA)**08.40**

Oligoarticular PsA: Lessons from longitudinal cohorts

Frank Behrens (DE)**09.05**

Learnings from PDE4 inhibition: Optimising outcomes for moderate PsA

Rubén Queiro (ES)**09.30**

Summary of the major learnings

All**09.35**

Audience Q&A

08.15 - 09.45 N117/N118

Menarini Group

Painful conditions in rheumatological diseases - A therapeutic strategy

Chair(s):

Serge Perrot (FR)

Serge Perrot (FR) 08.15

Introduction

Stefano Coaccioli (IT) 08.30

Inflammatory vs mechanical pain in musculo-skeletal diseases

Serge Perrot (FR) 08.50

Features of back pain: Which are the main rheumatological causes and its current treatments?

Magdi Hanna (UK) 09.10

Multimodal therapeutic strategy to address multiple mechanism of pain

All 09.30

Discussion and final remarks

08.15 - 09.45 N111/N112

GSK

From today's reality, to tomorrow's "Vision for Lupus"

Chair(s):

Chiara Tani (IT)

Chiara Tani (IT) 08.15

Welcome and introduction

Patricia Cagnoli (US) 08.30

Disease awareness: What is needed, how and why?

Chiara Tani (IT) 08.45

Integrated service delivery: The reality and what is possible?

Chris Edwards (UK) 09.05

Clinical research: Preparing the future together

Sue Mayor & Faculty 09.25

Interactive panel discussion: Your opportunity to engage the panel and share your experience

Chiara Tani (IT) 09.40

Closing remarks and call to action: What will you do to drive a change in lupus care?

17.30 - 19.00 N101/N102

Rheumatology Today

a service by: Chugai supported by: Roche & Novartis

German rheumatologists present their personal EULAR congress highlights

Chair(s):

Matthias Schneider (DE)

Speakers:

Peer M. Aries (DE)

Xenofon Baraliakos (DE)

Frank Behrens (DE)

Christof Iking-Konert (DE)

Christof Specker (DE)

Torsten Witte (DE)

Round table experts:

Frank Buttgereit (DE)

Jens Gert Kuipers (DE)

Ulf Müller-Ladner (DE)

Presentation of six trials presented at EULAR 2019 featuring the following topics:

- Axial spondylarthritis
- Biologica monotherapy
- Connective tissue diseases
- Novelties in RA treatment
- Psoriatic arthritis
- Vasculitis

17.30 - 19.00 N117/N118

RMEI

supported by Sanofi Genzyme & Regeneron Pharmaceuticals

Addressing real-world practice gaps in the management of RA

Chair(s):

Paul Emery (UK)

Faculty:

Leonard H. Calabrese (US)

Ernest Choy (UK)

Dinner reception & posters review **17.30**

Paul Emery (UK) 18.00

Welcome and introductions

Paul Emery (UK) 18.10

What do current gaps mean for patients?

All 18.20

Panel discussion #1: Pathologic mechanisms in RA and implications for management

All	18.40
Panel discussion #2: Standards for disease monitoring to guide treatment	
All	19.00
Panel discussion #3: Switching versus cycling and the role of new treatment options	
Paul Emery (UK)	19.20
Closing remarks	

17.30 - 19.00**N111/N112****Corbus Pharmaceuticals****The role of the endocannabinoid system in chronic inflammation and fibrosis****Chair(s):**

Christopher Denton (UK)

Tracy M. Frech (US)

Christopher Denton (UK)	17.30
Welcome and introduction	

Christopher Denton (UK)	17.55
Biology of the endocannabinoid system with a focus on inflammation and fibrosis	

Tracy M. Frech (US)	18.20
Targeting endocannabinoid system as a potential therapeutic in inflammatory/fibrotic diseases	